{"organizations": [], "uuid": "2ad55df95fcbe610e99ad193d401dec774ed4e1e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-cara-thera/brief-vifor-pharma-vfmcrp-and-cara-therapeutics-to-develop-and-commercialise-cr845-injection-for-chronic-kidney-disease-associated-pruritus-idUSFWN1SU08J", "country": "US", "domain_rank": 408, "title": "BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.823, "site_type": "news", "published": "2018-05-23T13:06:00.000+03:00", "replies_count": 0, "uuid": "2ad55df95fcbe610e99ad193d401dec774ed4e1e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-cara-thera/brief-vifor-pharma-vfmcrp-and-cara-therapeutics-to-develop-and-commercialise-cr845-injection-for-chronic-kidney-disease-associated-pruritus-idUSFWN1SU08J", "ord_in_thread": 0, "title": "BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus", "locations": [], "entities": {"persons": [{"name": "vifor", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - VIFOR PHARMA AG:\n* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T13:06:00.000+03:00", "crawled": "2018-05-24T20:16:59.029+03:00", "highlightTitle": ""}